Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19
Interim Guidance
27 September 2022
| COVID-19: Vaccines
Overview
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
For translations of this document in other languages, click here.
Related documents:
Archived versions:
WHO Team
Agenda, Policy & Strategy (APS),
Immunization, Vaccines and Biologicals (IVB),
Strategic Advisory Group of Experts on Immunization,
WHO Headquarters (HQ)
Number of pages
13
Reference numbers
WHO Reference Number: WHO/2019-nCoV/vaccines/SAGE_recommendation/Novavax_NVX-CoV2373/2021.1
Copyright
